<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26735603</article-id><article-id pub-id-type="pmc">4690661</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20150069</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association of Angiotensin-Converting Enzyme Genotype,
Insertion/Deletion Polymorphism and Saphenous Vein Graft Atherosclerosis in
Iranian Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zeinali</surname><given-names>Neda</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hashemi</surname><given-names>Mohammad</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mirmohammadsadeghi</surname><given-names>Mohsen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mirmohammadsadeghi</surname><given-names>Hamid</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Eskandari</surname><given-names>Nahid</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sabzghabaee</surname><given-names>Ali Mohammad</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="c1"/></contrib></contrib-group><aff id="aff1"><label>1</label>School of Pharmacy and Pharmaceutical Sciences, Isfahan University
of Medical Sciences, Isfahan, Iran.</aff><aff id="aff2"><label>2</label>Department of Cardiology, School of Medicine, Isfahan University of
Medical Sciences, Isfahan, Iran.</aff><aff id="aff3"><label>3</label>Department of Cardiothoracic Surgery, School of Medicine, Isfahan
University of Medical Sciences, Isfahan, Iran.</aff><aff id="aff4"><label>4</label>Department of Pharmaceutical Biotechnology, School of Pharmacy,
Isfahan University of Medical Sciences, Isfahan, Iran.</aff><aff id="aff5"><label>5</label>Department of Immunology, School of Medicine, Isfahan University of
Medical Sciences, Isfahan, Iran.</aff><aff id="aff6"><label>6</label>Isfahan Clinical Toxicology Research Center, Isfahan University of
Medical Sciences, Isfahan, Iran.</aff><author-notes><corresp id="c1">Correspondence Address: Ali Mohammad Sabzghabaee, Isfahan Clinical
Toxicology Research Center, Isfahan University of Medical Sciences, Hezarjerib
Ave., Isfahan 81746, Iran. E-mail: <email>sabzghaba@pharm.mui.ac.ir</email></corresp><fn fn-type="COI-statement"><p>Conflict of interest: All authors stated that they had no conflicts of
interest.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2015</year></pub-date><volume>30</volume><issue>5</issue><fpage>557</fpage><lpage>561</lpage><history><date date-type="received"><day>17</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p></license></permissions><abstract><sec><title>OBJECTIVE</title><p> The aim of this study was to evaluate possible interactions among
Angiotensin-I converting enzyme genotype, insertion/deletion polymorphism
and atherosclerosis of vein grafts in Iranian patients, and characterize
their clinical and demographic profile.</p></sec><sec><title>METHODS</title><p> In this cross-sectional study, patients who underwent coronary artery bypass
graft surgery more than five years ago, were included for angiographic
analysis. Atherosclerosis was determined by quantitative angiography and
adjusted Gensini score. The gene angiotensin converting enzyme I/D
polymorphism was detected by polymerase chain reaction.</p></sec><sec><title>RESULTS</title><p> A total of 102 patients participated in this study. Eighty-four patients
were male. The frequency distribution of DD, ID and II polymorphism were
23.6%, 62.7% and 13.7% respectively. There were no differences among
genotypic groups in age, sex, number of risk factors, number of vein grafts
and months since bypass surgery. According to adjusted Gensini score
[0.18&#x000b1;0.12 (II) <italic>vs.</italic> 0.11&#x000b1;0.09 (ID) and
0.1&#x000b1;0.09 (DD) <italic>P</italic>=0.021] the II genotype was
associated with severity of vein graft atherosclerosis.</p></sec><sec><title>CONCLUSION</title><p> Although there are conflicting results about gene angiotensin converting
enzyme I/D polymorphism and the degree of venous bypass graft degeneration,
this study suggests an association between ACE genotype II and
atherosclerosis of saphenous vein grafts, however, large samples considering
clinical, demographic and ethnic profile are necessary to confirm these
results.</p></sec></abstract><kwd-group><kwd>Cardiopulmonary Bypass</kwd><kwd>Cardiovascular Surgical Procedures</kwd><kwd>Genetics</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="float"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th colspan="2" align="left" rowspan="1">
<bold>Abbreviations, acronyms &#x00026; symbols</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ACE </td><td rowspan="1" colspan="1">= Angiotensin-converting enzyme </td></tr><tr><td rowspan="1" colspan="1">CABG</td><td rowspan="1" colspan="1"> = Coronary artery bypass graft </td></tr><tr><td rowspan="1" colspan="1">PCR</td><td rowspan="1" colspan="1"> = Polymerase chain reaction</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Coronary artery bypass graft surgery (CABG) still remains the standard care for
patients with multivessel coronary artery disease comparing to percutaneous coronary
intervention (PCI). This maybe due to its lower rates of major adverse cardiac and
cerebrovascular events in short-term and long-term periods<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>A majority of patients receive saphenous vein grafting (SVG) to most vessels, with
the exception of the left anterior descending coronary artery<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Large diameter and wall
characteristics, being plentiful, long and easy harvest has made SVG the most
commonly used conduit, but its longevity, as compared with arterial graft, is not
satisfying. SVG patency is 95% at 1 week, 84% at 1 year, 80% at 3 years, 69% at 6
years, and 61% at 10 years after operation<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. Thrombosis, intimal hyperplasia and
atherosclerosis account for graft failure in early (less than 1 month), subacute
(one to 12 months) and late (more than 12 months) post CABG
periods<sup>[<xref rid="r8" ref-type="bibr">8</xref>-<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>During past decades, many studies have shown genetic risk factors are as important as
conventional risk factors in the development and progression of
atherosclerosis<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Clinical assessment of the relationship between
preoperative use of angiotensin-converting enzyme (ACE) inhibitors and clinical
outcomes after CABG is discussed elsewhere<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. One of the most significant genetic risk
factors is the ACE gene insertion/deletion (I/D) polymorphism<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. ACE encoding gene is
located on chromosome 17 (17q23) and the presence (insertion) or absence (deletion)
of a 287-bp alu repeat sequence in intron 16 of the gene results in ACE (I/D)
polymorphism. This polymorphism accounts for 47% of variations in ACE
levels<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>ACE is a key regulator in the renin angiotensin system (RAS) which converts
Angiotensin I into Angiotensin II (Ang II)<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Ang II, the atherogenic component of the
RAS, develops atheroma. Ang II increases vascular permeability and induces
expression of inflammatory mediators such as cytokines, chemokines and adhesion
molecules<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. It also stimulates proliferation and migration of
vascular smooth muscle cells and extracellular matrix deposition<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Ang II plays a role in
oxidative stress by activating nicotinamide dinucleotide phosphate (NADPH) oxidase
to produce reactive oxygen species (ROS)<sup>[<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>To our best of knowledge, the association of ACE (I/D) polymorphism and venous bypass
graft degeneration in long-term periods has not been studied in Iranian patients, so
the aim of this study was to evaluate possible interactions between ACE (I/D)
polymorphism and atherosclerosis of vein grafts in Iranian patients, and
characterize their clinical and demographic profile.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The research protocol of this cross-sectional study was approved by the institutional
board of research ethics for human studies at the Isfahan University of Medical
Sciences (Research project number # 389305).</p><sec><title>Study population</title><p>Study population consisted of 102 patients who have undergone CABG more than 5
years ago and were referred to Sina Hospital and Noor University Hospital
(located in Isfahan, Iran) for coronary angiography due to coronary heart
disease (CHD) symptoms from December 2010 to October 2011.Medical histories of
all patients were obtained and CHD conventional risk factors were evaluated
according to these criteria: high blood pressure (systolic blood pressure
&#x0003e;140 mmHg and diastolic blood pressure &#x0003e;90 mmHg or taking antihypertensive
agents), hypercholesterolemia (total cholestero &#x0003e;240 mg/dL or taking lipid
lowering agents), diabetes mellitus (fasting blood glucose &#x0003e;110 mg/dL or
taking anti hyperglycemic agents), cigarette smoking (daily habit) and positive
family history (men &#x0003c;55 years old and women &#x0003c;65 years old in first degree
of relatives).</p></sec><sec><title>Vein graft angiography</title><p>Cardiac catheterization and vein graft angiography was performed using Judkins
technique<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> and percutaneos femoral artery approach. Vein graft
bed was divided into three segments: proximal, middle and distal. The severity
of venous bypass graft atherosclerosis was quantified according to Gensini
score. Gensini score was defined by grading of reduction in vessel lumen
diameter. Narrowing of 25%, 50%, 75%, 90%, 99% and 100% were equivalent to
Gensini score of 1, 2, 4, 8, 16 and 32 respectively<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. The Gensini score of
three segments of each vein graft were added and the mean of the Gensini score
of total vein grafts in each patient was obtained to reflect the degree of
atherosclerosis. For illustrating the rate of bypass degeneration, the mean of
Gensini score was divided by the months after CABG (adjusted Gensini score: The
mean of Gensini score/months after surgery).</p></sec><sec><title>Determination of ACE genotypes</title><p>Genomic DNAs were extracted from whole blood leucocytes using DNA isolation kit
(High Pure PCR Template Preparation kit, Roche Diagnostics GmbH, Germany).
Extracted DNAs were stored at -20&#x000b0;C for future polymerase chain reaction (PCR).
Two PCRs with four primers were carried out for detection of ACE intron 16 I/D
polymorphism. The first PCR primers were 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3'
(forward primer) and 5'GAT GTG GCC ATC ACA TTC GTC AGA T-3' (reverse primer).
Final volume of PCR reaction mixture was 25&#x000b5;l that contained 12.5 pmol of
each primer, 2.8 mM MgCl2, 0.8 mM of each dNTp, 2.5 &#x000b5;l of 10X High
Fidelity PCR Buffer (Fermentase) and 1 U of Taq polymerase (High Fidelity PCR
Enzyme Mix, Fermentase).</p><p>Amplification was performed in DNA Thermal Cycler (Analytic Jena) with initial
denaturation step at 94&#x000b0;C for 5 min followed by 30 cycles consisting of
denaturation at 94&#x000b0;C for 1 min, annealing at 58&#x000b0;C for 1 min and extension at
72&#x000b0;C for 2 min, followed by final extension step at 72&#x000b0;C for 5 min. PCR products
were separated on 1% agarose gel and DNA was visualized by ethidium bromide
staining on UV transillumination imaging system. DNA fragment sizes were 190 bp
for the D allele and 490 bp for the I allele.</p><p>To avoid DD mistyping, second PCR was carried out on DD genotype
samples<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Second PCR was performed with an specific
insertion primer pairs included 5'-TGG GAC CAC AGC GCC CGC CAC TAC-3' as a
forward primer and 5'-TCG CCA GCC CTC CCA TGC CCA TAA-3' as a reverse primer in
25 &#x000b5;l reaction mixture volume. Second PCR steps consisted of initial
denaturation at 94&#x000b0;C for 1 min followed by 30 cycles of denaturation at 94&#x000b0;C for
30 s, annealing at 67&#x000b0;C for 45 s and extension at 72&#x000b0;C for 2 min followed by
final extension at 72&#x000b0;C for 5 min. Positive control samples (samples showed II
genotype in first PCR) were used to confirm the reliability of genotyping.
Presence of I allele resulted in PCR product of 335 bp.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was carried out using SPSS version 20.0 and data were
expressed as the mean&#x000b1;SD or percentage. Chi-square test, Fisher's exact
test or Kruskal-Wallis test (where appropriate) was used for non-parametric
variables and independent t-student test or one-way ANOVA test was used for
analyzing the numerical data. <italic>P</italic>&#x0003c;0.05 was considered
statistically significant. If statistically significant <italic>P</italic> value
obtained by ANOVA, Bonferroni's post-hoc test was performed for pair wise
comparison.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Demographic characteristics of the study population</title><p>Demographic characteristics and clinical features of the study population are
shown in <xref ref-type="table" rid="t1">Table 1</xref>. The mean of months
since CABG was 128.7&#x000b1;38.36. The proportion of occluded, diseased and free
of atherosclerosis vein grafts were 42.12%, 26% and 31.88% respectively.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic characteristics and clinical features of the studied patients
with vein graft atherosclerosis.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">N (%) / Mean&#x000b1;SD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">102</td></tr><tr><td rowspan="1" colspan="1">Sex (Female/Male)</td><td align="left" rowspan="1" colspan="1">18 (17.6)/84 (82.4)</td></tr><tr><td rowspan="1" colspan="1">Age (year)</td><td align="left" rowspan="1" colspan="1">64.89&#x000b1;8.54</td></tr><tr><td rowspan="1" colspan="1">Body Mass Index (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">26.52&#x000b1;3.68</td></tr><tr><td rowspan="1" colspan="1">Hypertension (positive)</td><td align="left" rowspan="1" colspan="1">62 (60.8)</td></tr><tr><td rowspan="1" colspan="1">Hypercholesterolemia (positive)</td><td align="left" rowspan="1" colspan="1">95 (93.1)</td></tr><tr><td rowspan="1" colspan="1">Diabetes mellitus (positive)</td><td align="left" rowspan="1" colspan="1">30 (29.4)</td></tr><tr><td rowspan="1" colspan="1">Cigarette smoking (positive)</td><td align="left" rowspan="1" colspan="1">17 (16.7)</td></tr><tr><td rowspan="1" colspan="1">Family history (positive)</td><td align="left" rowspan="1" colspan="1">68 (66.7)</td></tr><tr><td rowspan="1" colspan="1">Total Coronary Heart Disease risk factors</td><td align="left" rowspan="1" colspan="1">3 (1-5)<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="1" colspan="1">Total number of vein grafts</td><td align="left" rowspan="1" colspan="1">254</td></tr><tr><td rowspan="1" colspan="1">Left anterior descending</td><td align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">Left circumflex</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">Diagonal</td><td align="left" rowspan="1" colspan="1">54</td></tr><tr><td rowspan="1" colspan="1">Optus margin</td><td align="left" rowspan="1" colspan="1">95</td></tr><tr><td rowspan="1" colspan="1">Right coronary artery</td><td align="left" rowspan="1" colspan="1">81</td></tr><tr><td rowspan="1" colspan="1">Ramous</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">Occluded vein grafts</td><td align="left" rowspan="1" colspan="1">107</td></tr><tr><td rowspan="1" colspan="1">Diseased vein grafts</td><td align="left" rowspan="1" colspan="1">66</td></tr><tr><td rowspan="1" colspan="1">Free of atherosclerosis</td><td align="left" rowspan="1" colspan="1">81</td></tr><tr><td rowspan="1" colspan="1">Number of vein grafts per patient</td><td align="left" rowspan="1" colspan="1">3 (1-5)<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="1" colspan="1">Months elapsed from Coronary Artery Bypass Graft surgery</td><td align="left" rowspan="1" colspan="1">128.7&#x000b1;38.36</td></tr><tr><td rowspan="1" colspan="1">Vein graft Gensini score<xref ref-type="table-fn" rid="TFN02">**</xref></td><td align="left" rowspan="1" colspan="1">13.99&#x000b1;11.41</td></tr><tr><td rowspan="1" colspan="1">Adjusted vein graft Gensini score<xref ref-type="table-fn" rid="TFN03">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">0.11&#x000b1;0.1</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><label>*</label><p>Median (range)</p></fn><fn id="TFN02"><label>**</label><p>Vein graft Gensini score: the mean of Gensini score of total grafts
in each patient</p></fn><fn id="TFN03"><label>&#x02020;</label><p>Adjusted vein graft Gensini score: vein graft Gensini score was
divided by months elapsed from Coronary Artery Bypass Graft
surgery</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Genotype and allele frequencies</title><p>The genotype and allele frequencies are listed in <xref ref-type="table" rid="t2">Table 2</xref>. Observed genotype and allele frequencies of ACE I/D
polymorphism were in Hardy-Weinberg equilibrium in the study population.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Genotype and allele frequencies of ACE I/D polymorphism in studied
patients with vein graft atherosclerosis.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="center" rowspan="1" colspan="1">ACE I/D polymorphism</th><th align="center" rowspan="1" colspan="1">Genotype</th><th align="center" rowspan="1" colspan="1">N (%)</th><th align="center" rowspan="1" colspan="1">Allele</th><th align="center" rowspan="1" colspan="1">N (Absolute frequency)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">14 (13.7)</td><td align="center" rowspan="1" colspan="1">D</td><td align="center" rowspan="1" colspan="1">112 (0.55)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">ID</td><td align="center" rowspan="1" colspan="1">64 (62.7)</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">92 (0.45)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">DD</td><td align="center" rowspan="1" colspan="1">24 (23.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN04"><p>ACE=Angiotensin Converting Enzyme</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Relationship between ACE I/D polymorphism and progression of atheromatous
plaque in vein graft</title><p>Relationship between ACE I/D polymorphism and severity of vein graft
atherosclerosis and comparison of the number of occluded, diseased and free of
atherosclerosis vein grafts, number of vein grafts, months after CABG and number
of CHD risk factors according to genotype are reported in <xref ref-type="table" rid="t3">Table 3</xref>. According to Gensini score, ACE I/D polymorphism
was associated with progression and development of atherosclerosis in venous
bypass grafts (<italic>P</italic>=0.02). Bonferroni's post hoc- test showed
patients who were homozygous for I allele had higher adjusted Gensini score and
rate of atherosclerosis (<xref ref-type="table" rid="t4">Table 4</xref>).
Although there was no statistical difference in the number of diseased vein
grafts per genotype, Gensini score showed bypass degeneration was more severe in
II genotype. Without regarding adjusted Gensini score, ACE II genotype resulted
in vein graft failure in earlier postoperative period (statistically marginal
significant difference in months after CABG, <italic>P</italic>=0.06).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Effect of ACE I/D polymorphism on progression of atherosclerosis in vein
grafts of the studied patients.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">ACE I/D polymorphism</th><th align="left" rowspan="1" colspan="1">II</th><th align="left" rowspan="1" colspan="1">ID</th><th align="left" rowspan="1" colspan="1">DD</th><th align="left" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Adjusted Gensini score, Mean (&#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">0.18&#x000b1;0.12</td><td align="left" rowspan="1" colspan="1">0.11+0.09</td><td align="left" rowspan="1" colspan="1">0.1+0.09</td><td align="left" rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of occluded vein grafts, Median (Range)</td><td align="left" rowspan="1" colspan="1">1 (0-4)</td><td align="left" rowspan="1" colspan="1">1 (0-3)</td><td align="left" rowspan="1" colspan="1">1 (0-4)</td><td align="left" rowspan="1" colspan="1">0.64<xref ref-type="table-fn" rid="TFN07">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of diseased vein grafts, Median (Range)</td><td align="left" rowspan="1" colspan="1">0 (0-2)</td><td align="left" rowspan="1" colspan="1">1 (0-2)</td><td align="left" rowspan="1" colspan="1">0.5 (0-3)</td><td align="left" rowspan="1" colspan="1">0.84<xref ref-type="table-fn" rid="TFN07">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of free of atherosclerosis vein grafts,
Median (Range)</td><td align="left" rowspan="1" colspan="1">0 (0-2)</td><td align="left" rowspan="1" colspan="1">1 (0-3)</td><td align="left" rowspan="1" colspan="1">1 (0-4)</td><td align="left" rowspan="1" colspan="1">0.27<xref ref-type="table-fn" rid="TFN07">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of vein grafts, Median (Range)</td><td align="left" rowspan="1" colspan="1">2 (1-4)</td><td align="left" rowspan="1" colspan="1">2 (1-5)</td><td align="left" rowspan="1" colspan="1">3 (1-5)</td><td align="left" rowspan="1" colspan="1">0.41<xref ref-type="table-fn" rid="TFN07">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Months post CABG, Mean (&#x000b1; SD)</td><td align="left" rowspan="1" colspan="1">1 12.07&#x000b1;32.46</td><td align="left" rowspan="1" colspan="1">135.02&#x000b1;38.33</td><td align="left" rowspan="1" colspan="1">121.04&#x000b1;38.67</td><td align="left" rowspan="1" colspan="1">0.06<xref ref-type="table-fn" rid="TFN06">*</xref></td></tr><tr style="border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">Number of CHD risk factors, Median (Range)</td><td align="left" rowspan="1" colspan="1">2 (1-4)</td><td align="left" rowspan="1" colspan="1">3 (0-5)</td><td align="left" rowspan="1" colspan="1">2.5 (1-4)</td><td align="left" rowspan="1" colspan="1">0.58<xref ref-type="table-fn" rid="TFN07">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN05"><p>ACE=angiotensin converting enzyme, CABG=coronary artery bypass graft
surgery</p></fn><fn id="TFN06"><label>*</label><p>One-wayAnova test,</p></fn><fn id="TFN07"><label>**</label><p>Kruskal-Wallis test</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of angiographic severity of coronary artery disease in
different ACE genotypes.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="left" rowspan="1" colspan="1">ACE genotype</th><th align="left" rowspan="1" colspan="1">Adjusted Gensini score</th><th align="left" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">II <italic>vs.</italic> ID</td><td align="left" rowspan="1" colspan="1">0.18&#x000b1;0.12 <italic>vs.</italic>
0.11&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.029*</td></tr><tr><td align="left" rowspan="1" colspan="1">II <italic>vs.</italic> DD</td><td align="left" rowspan="1" colspan="1">0.18&#x000b1;0.12 <italic>vs.</italic>
0.1&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.032*</td></tr><tr style="border-bottom-style:solid"><td align="left" rowspan="1" colspan="1">ID <italic>vs.</italic> DD</td><td align="left" rowspan="1" colspan="1">0.11&#x000b1;0.09 <italic>vs.</italic>
0.1&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">1*</td></tr></tbody></table><table-wrap-foot><fn id="TFN08"><p>ACE=angiotensin converting enzyme, independent t-student test</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The results of our study show that ACE II genotype could be considered a risk factor
for long-term graft failure after CABG. ACE II may have some roles in the
progression of atheromatous plaque of vein grafts in earlier postoperative periods
as compared with two other genotypic groups. Few studies about the influence of ACE
I/D polymorphism on venous bypass graft atherosclerosis are available. Studies
carried out in Turkey and Germany demonstrated different results<sup>[<xref rid="r25" ref-type="bibr">25</xref>-<xref rid="r27" ref-type="bibr">27</xref>]</sup>. Ortlepp et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> reported ACE I/D
polymorphism was not associated with venous bypass degeneration in the long term in
their 101 studied patients. Dayi et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> indicated DD genotype influenced vein graft
occlusion in late postoperative period in their 87 consecutively selected patients.
On the other hand, our study shows no statistical difference among ACE genotypic
groups and the number of occluded vein grafts (<italic>P</italic>=0.64,
Kruskal-Wallis test). In a study done by V&#x000f6;lzke et al.<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup> on 247 patients, they
demonstrated ACE DD genotype increased the rate of mortality and cardiovascular
morbidity in the midterm after CABG.</p><p>Although ACE DD genotype was associated with the increasing risk of cardiovascular
disease in many studies, some studies reported other type of genotypes as risk
factors. Zee et al.<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup> showed I allele was risk factor for essential
hypertension. Ismail et al.<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup> found significantly higher frequency of ACE II genotype
in hypertensive patients aged 20-40 years. In Northern Indian population I allele
was associated with essential hypertension<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. ACE ID genotype was responsible for
peripheral vascular disease in Western Turkish patients<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>.</p><p>The results of the study of ACE I/D polymorphism and cardiovascular disease in
Iranian population seem conflicting. The presence of D allele exacerbated the risk
of early onset coronary artery disease in west population of Iran<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>. Shafiee et
al.<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>
showed different results. They reported no association between ACE DD genotype and
the risk of coronary artery disease. They collected study population from patients
referred to Shahid Rajaei Cardiovascular Medical and Research Center, Tehran,
Iran<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>.
Despite the adverse effect of ACE DD genotype on hypertension in type 2 diabetic
population reported by Nakhjavani et al.<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>, Nikzamir et al.<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup> found no relation between ACE I/D
polymorphism and the presence of metabolic syndrome in patients with type 2
diabetes.</p><p>In our study the frequency distribution of II, ID and DD genotype are 13.7%, 62.7%
and 23.6% respectively. These values are similar to the results found by Nikzamir et
al.<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>
(16.5%, 58.2% and 25.3%), but are different from the data reported by Vaisi-Raygani
et al.<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup> (17.3%,
40% and 42.7%), Shafiee et al.<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup> (16.22%, 32.24% and 51.51%) and Nakhjavani et
al.<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>
(27.5%, 50% and 22.5%). Frequency distribution of ACE I/D polymorphism observed in
various parts of Iran is different and it may be responsible for the discrepancies
in the reported results. It seems that different ACE I/D polymorphism interactions
with cardiovascular disease could be attributed to the various ethnicities studied
in previously mentioned Iranian studies.</p><p>We also think that the heterogeneity of our sample considering clinical profile,
pharmacological treatment and lifestyle, as well as the surgical technique for
myocardial revascularization, could influence the follow-up as well as its relation
with the genetic profile. Lack of serum ACE activity measurement and also the small
sample size are main limitations of this study.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Although there are conflicting results about ACE I/D polymorphism and the degree of
venous bypass graft degeneration, this study suggests an association between ACE
genotype II and atherosclerosis of saphenous vein grafts, however, large samples
considering clinical, demographic and ethnic profile are necessary to confirm these
results.</p><table-wrap id="t6" orientation="portrait" position="float"><table frame="hsides" rules="groups"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th colspan="3" align="left" rowspan="1">
<bold>Authors' roles &#x00026; responsibilities</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">NZ</td><td colspan="2" rowspan="1">Collected the data and helped in data analysis; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">MH</td><td colspan="2" rowspan="1">Contributed in designing and conducting the study; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">MM</td><td colspan="2" rowspan="1">Contributed in designing and conducting the study; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">HM</td><td colspan="2" rowspan="1">Rechecked the statistical analysis and revised the
manuscript; final approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">NE</td><td colspan="2" rowspan="1">Rechecked the statistical analysis and revised the
manuscript; final approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">AMS</td><td colspan="2" rowspan="1">Proposed the idea; managed the research project;
rechecked the statistical analysis; prepared the manuscript and
final approval of the manuscript</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the school of Pharmacy and Pharmaceutical Sciences,
Isfahan University of Isfahan University of Medical Sciences, Isfahan, Iran.</p></fn><fn fn-type="supported-by"><p>Financial Support: This study is result of a Doctor of Pharmacy thesis project
which was financially supported by the Vice-Chancellery for Research and
Technology of the Isfahan University of Medical Sciences.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>This study is result of a Doctor of Pharmacy thesis project which was financially
supported by the Vice-Chancellery for Research and Technology of the Isfahan
University of Medical Sciences. Authors would like to thank all personnel of the
poisoning emergency room of the Noor and Ali-Asghar [PBUH] University
Hospital for their sincere help. Authors would like to thank Mr. Rory O'Conner for
final English editing.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marui</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Nishiwaki</surname><given-names>N</given-names></name><name><surname>Mitsudo</surname><given-names>K</given-names></name><name><surname>Komiya</surname><given-names>T</given-names></name><name><surname>Hanyu</surname><given-names>M</given-names></name><etal/><collab>CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators</collab></person-group><article-title>Comparison of five-year outcomes of coronary artery bypass
grafting versus percutaneous coronary intervention in patients with left
ventricular ejection fractions &#x00026;le; 50% versus &#x00026;gt;50% (from the
CREDO-Kyoto PCI/CABG Registry Cohort-2)</article-title><source>Am J Cardiol</source><year>2014</year><volume>114</volume><issue>7</issue><fpage>988</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">25124184</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><etal/><collab>SYNTAX Investigators</collab></person-group><article-title>Percutaneous coronary intervention versus coronary-artery bypass
grafting for severe coronary artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>10</issue><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">19228612</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daemen</surname><given-names>J</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Flather</surname><given-names>M</given-names></name><name><surname>Booth</surname><given-names>J</given-names></name><name><surname>Stables</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term safety and efficacy of percutaneous coronary
intervention with stenting and coronary artery bypass surgery for
multivessel coronary artery disease: a meta-analysis with 5-year
pa-tient-level data from the ARTS, ERACI-II, MASS-II, and SoS
trials</article-title><source>Circulation</source><year>2008</year><volume>118</volume><issue>11</issue><fpage>1146</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">18725490</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hlatky</surname><given-names>MA</given-names></name><name><surname>Boothroyd</surname><given-names>DB</given-names></name><name><surname>Bravata</surname><given-names>DM</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Booth</surname><given-names>J</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Coronary artery bypass surgery compared with percutaneous
coronary interventions for multivessel disease: a collaborative analysis of
individual patient data from ten randomised trials</article-title><source>Lancet</source><year>2009</year><volume>373</volume><issue>9670</issue><fpage>1190</fpage><lpage>1197</lpage><pub-id pub-id-type="pmid">19303634</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;</surname><given-names>MPBO</given-names></name><name><surname>Ferraz</surname><given-names>PE</given-names></name><name><surname>Escobar</surname><given-names>RR</given-names></name><name><surname>Nunes</surname><given-names>EO</given-names></name><name><surname>Soares</surname><given-names>AMMN</given-names></name><name><surname>S&#x000e1;</surname><given-names>FBCA</given-names></name><etal/></person-group><article-title>Five-year outcomes following PCI with DES versus CABG for
unprotected LM coronary lesions: meta-analysis and meta-regression of 2914
patients</article-title><source>Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><issue>1</issue><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">23739937</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>O</given-names></name><name><surname>Gonca</surname><given-names>S</given-names></name><name><surname>Solakoglu</surname><given-names>S</given-names></name><name><surname>Dalcik</surname><given-names>H</given-names></name><name><surname>Dalcik</surname><given-names>C</given-names></name><name><surname>Ozkara</surname><given-names>A</given-names></name></person-group><article-title>Comparison of conventional and no-touch techniques in harvesting
saphenous vein for coronary artery bypass grafting in view of endothelial
damage</article-title><source>Heart Surg Forum</source><year>2013</year><volume>16</volume><issue>4</issue><fpage>E177</fpage><lpage>E183</lpage><pub-id pub-id-type="pmid">23958526</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabik 3rd</surname><given-names>JF</given-names></name></person-group><article-title>Understanding saphenous vein graft patency</article-title><source>Circulation</source><year>2011</year><volume>124</volume><issue>3</issue><fpage>273</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">21768550</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harskamp</surname><given-names>RE</given-names></name><name><surname>Lopes</surname><given-names>RD</given-names></name><name><surname>Baisden</surname><given-names>CE</given-names></name><name><surname>de Winter</surname><given-names>RJ</given-names></name><name><surname>Alexander</surname><given-names>JH</given-names></name></person-group><article-title>Saphenous vein graft failure after coronary artery bypass
surgery: pathophysiology, management, and future directions</article-title><source>Ann Surg</source><year>2013</year><volume>257</volume><issue>5</issue><fpage>824</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">23574989</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>N</given-names></name><name><surname>Jeremy</surname><given-names>JY</given-names></name></person-group><article-title>Pathophysiology of saphenous vein graft failure: a brief overview
of interventions</article-title><source>Curr Opin Pharmacol</source><year>2012</year><volume>12</volume><issue>2</issue><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">22321569</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parang</surname><given-names>P</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name></person-group><article-title>Coronary vein graft disease: pathogenesis and
prevention</article-title><source>Can J Cardiol</source><year>2009</year><volume>25</volume><issue>2</issue><fpage>e57</fpage><lpage>e62</lpage><pub-id pub-id-type="pmid">19214303</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belczak</surname><given-names>CEQ</given-names></name><name><surname>Tyszka</surname><given-names>AL</given-names></name><name><surname>Godoy</surname><given-names>JMP</given-names></name><name><surname>Ramos</surname><given-names>RN</given-names></name><name><surname>Belczak</surname><given-names>SQ</given-names></name><name><surname>Caffaro</surname><given-names>RA</given-names></name></person-group><article-title>Clinical complications of limb undergone harvesting of great
saphenous vein for coronary artery bypass grafting using bridge
technique</article-title><source>Rev Bras Cir Cardiovasc</source><year>2009</year><volume>24</volume><issue>1</issue><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">19504022</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>H</given-names></name><name><surname>Bhardwaj</surname><given-names>S</given-names></name><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name></person-group><article-title>Molecular genetics of atherosclerosis</article-title><source>Hum Genet</source><year>2009</year><volume>125</volume><issue>5-6</issue><fpage>467</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">19301036</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Baird</surname><given-names>AE</given-names></name><name><surname>Barkley</surname><given-names>RA</given-names></name><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Ganesh</surname><given-names>SK</given-names></name><etal/><collab>American Heart Association Council on Epidemiology and
Prevention</collab><collab>American Heart Association Stroke Council</collab><collab>Functional Genomics and Translational Biology Interdisciplinary
Working Group</collab></person-group><article-title>Relevance of genetics and genomics for prevention and treatment
of cardiovascular disease: a scientific statement from the American Heart
Association Council on Epidemiology and Prevention, the Stroke Council, and
the Functional Genomics and Translational Biology Interdisciplinary Working
Group</article-title><source>Circulation</source><year>2007</year><volume>115</volume><issue>22</issue><fpage>2878</fpage><lpage>2901</lpage><pub-id pub-id-type="pmid">17515457</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radaelli</surname><given-names>G</given-names></name><name><surname>Bodanese</surname><given-names>LC</given-names></name><name><surname>Guaragna</surname><given-names>JCVC</given-names></name><name><surname>Borges</surname><given-names>AP</given-names></name><name><surname>Goldani</surname><given-names>MA</given-names></name><name><surname>Petracco</surname><given-names>JB</given-names></name><etal/></person-group><article-title>The use of inhibitors of angiotensin-converting enzyme and its
relation to events in the postoperative period of CABG</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>3</issue><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">22086573</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Raman</surname><given-names>G</given-names></name><name><surname>Kitsios</surname><given-names>G</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Angiotensin-converting enzyme insertion/deletion gene polymorphic
variant as a marker of coronary artery disease: a
meta-analysis</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><issue>10</issue><fpage>1077</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">18504336</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urhan K&#x000fc;&#x000e7;&#x000fc;k</surname><given-names>M</given-names></name><name><surname>Sucu</surname><given-names>N</given-names></name><name><surname>Sahan Firat</surname><given-names>S</given-names></name><name><surname>Ayta&#x000e7;oglu</surname><given-names>BN</given-names></name><name><surname>Vezir</surname><given-names>&#x000d6;</given-names></name><name><surname>Bozali</surname><given-names>C</given-names></name><etal/></person-group><article-title>Role of ACE I/D gene polymorphisms on the effect of ramipril in
inflammatory response and myocardial injury in patients undergoing coronary
artery bypass grafts</article-title><source>Eur J Clin Pharmacol</source><year>2014</year><volume>70</volume><issue>12</issue><fpage>1443</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">25256070</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teranishi</surname><given-names>J</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Nagasawa</surname><given-names>Y</given-names></name><name><surname>Shoji</surname><given-names>T</given-names></name><name><surname>Iwatani</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>N</given-names></name><etal/></person-group><article-title>ACE insertion/deletion polymorphism (rs1799752) modifies the
renoprotective effect of renin-angiotensin system blockade in patients with
IgA nephropathy</article-title><source>J Renin Angiotensin Aldosterone Syst</source><year>2015</year><volume>16</volume><issue>3</issue><fpage>633</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">24452035</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacurari</surname><given-names>M</given-names></name><name><surname>Kafoury</surname><given-names>R</given-names></name><name><surname>Tchounwou</surname><given-names>PB</given-names></name><name><surname>Ndebele</surname><given-names>K</given-names></name></person-group><article-title>The Renin-Angiotensin-aldosterone system in vascular inflammation
and remodeling</article-title><source>Int J Inflam</source><year>2014</year><volume>2014</volume><fpage>689360</fpage><lpage>689360</lpage><pub-id pub-id-type="pmid">24804145</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms associated with Angiotensin-converting
enzyme-inhibitory peptide activity on vascular extracellular matrix
remodeling</article-title><source>Cardiology</source><year>2014</year><volume>127</volume><issue>4</issue><fpage>247</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">24480854</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zablocki</surname><given-names>D</given-names></name><name><surname>Sadoshima</surname><given-names>J</given-names></name></person-group><article-title>Angiotensin II and oxidative stress in the failing
heart</article-title><source>Antioxid Redox Signal</source><year>2013</year><volume>19</volume><issue>10</issue><fpage>1095</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">22429089</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikalov</surname><given-names>SI</given-names></name><name><surname>Nazarewicz</surname><given-names>RR</given-names></name><name><surname>Bikineyeva</surname><given-names>A</given-names></name><name><surname>Hilenski</surname><given-names>L</given-names></name><name><surname>Lass&#x000e8;gue</surname><given-names>B</given-names></name><name><surname>Griendling</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Nox2-induced production of mitochondrial superoxide in
angiotensin II-mediated endothelial oxidative stress and
hypertension</article-title><source>Antioxid Redox Signal</source><year>2014</year><volume>20</volume><issue>2</issue><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">24053613</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldroyd</surname><given-names>KG</given-names></name><name><surname>Phadke</surname><given-names>KV</given-names></name><name><surname>Phillips</surname><given-names>R</given-names></name><name><surname>Carson</surname><given-names>PH</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>JA</given-names></name></person-group><article-title>Cardiac catheterisation by the Judkins technique as an outpatient
procedure</article-title><source>BMJ</source><year>1989</year><volume>298</volume><issue>6677</issue><fpage>875</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">2497831</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gensini</surname><given-names>GG</given-names></name></person-group><article-title>A more meaningful scoring system for determining the severity of
coronary heart disease</article-title><source>Am J Cardiol</source><year>1983</year><volume>51</volume><issue>3</issue><fpage>606</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">6823874</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugam</surname><given-names>V</given-names></name><name><surname>Sell</surname><given-names>KW</given-names></name><name><surname>Saha</surname><given-names>BK</given-names></name></person-group><article-title>Mistyping ACE heterozygotes</article-title><source>PCR Methods Appl</source><year>1993</year><volume>3</volume><issue>2</issue><fpage>120</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">8268786</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortlepp</surname><given-names>JR</given-names></name><name><surname>Janssens</surname><given-names>U</given-names></name><name><surname>Bleckmann</surname><given-names>F</given-names></name><name><surname>Lauscher</surname><given-names>J</given-names></name><name><surname>Merkelbach-Bruse</surname><given-names>S</given-names></name><name><surname>Hanrath</surname><given-names>P</given-names></name><etal/></person-group><article-title>A chymase gene variant is associated with atherosclerosis in
venous coronary artery bypass grafts</article-title><source>Coron Artery Dis</source><year>2001</year><volume>12</volume><issue>6</issue><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">11696688</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayi</surname><given-names>SU</given-names></name><name><surname>Tartan</surname><given-names>Z</given-names></name><name><surname>Terzi</surname><given-names>S</given-names></name><name><surname>Kasikcioglu</surname><given-names>H</given-names></name><name><surname>Uyarel</surname><given-names>H</given-names></name><name><surname>Orhan</surname><given-names>G</given-names></name><etal/></person-group><article-title>Influence of angiotensin converting enzyme insertion/deletion
polymorphism on long-term total graft occlusion after coronary artery bypass
surgery</article-title><source>Heart Surg Forum</source><year>2005</year><volume>8</volume><issue>5</issue><fpage>E373</fpage><lpage>E377</lpage><pub-id pub-id-type="pmid">16146835</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000f6;lzke</surname><given-names>H</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Kleine</surname><given-names>V</given-names></name><name><surname>Schwahn</surname><given-names>C</given-names></name><name><surname>Dahm</surname><given-names>JB</given-names></name><name><surname>Eckel</surname><given-names>L</given-names></name><etal/></person-group><article-title>Angiotensin I-converting enzyme insertion/deletion polymorphism
and cardiac mortality and morbidity after coronary artery bypass graft
surgery</article-title><source>Chest</source><year>2002</year><volume>122</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12114335</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname><given-names>RY</given-names></name><name><surname>Lou</surname><given-names>YK</given-names></name><name><surname>Griffiths</surname><given-names>LR</given-names></name><name><surname>Morris</surname><given-names>BJ</given-names></name></person-group><article-title>Association of a polymorphism of the angiotensin I-converting
enzyme gene with essential hypertension</article-title><source>Biochem Biophys Res Commun</source><year>1992</year><volume>184</volume><issue>1</issue><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">1314601</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ismail</surname><given-names>M</given-names></name><name><surname>Akhtar</surname><given-names>N</given-names></name><name><surname>Nasir</surname><given-names>M</given-names></name><name><surname>Firasat</surname><given-names>S</given-names></name><name><surname>Ayub</surname><given-names>Q</given-names></name><name><surname>Khaliq</surname><given-names>S</given-names></name></person-group><article-title>Association between the angiotensin-converting enzyme gene
insertion/deletion polymorphism and essential hypertension in young
Pakistani patients</article-title><source>J Biochem Mol Biol</source><year>2004</year><volume>37</volume><issue>5</issue><fpage>552</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">15479618</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>K</given-names></name><name><surname>Sundriyal</surname><given-names>R</given-names></name><name><surname>Meena</surname><given-names>PC</given-names></name><name><surname>Bhatia</surname><given-names>J</given-names></name><name><surname>Narang</surname><given-names>R</given-names></name><name><surname>Saluja</surname><given-names>D</given-names></name></person-group><article-title>Association of angiotensin converting enzyme (insertion/deletion)
gene polymorphism with essential hypertension in northern Indian
subjects</article-title><source>Genet Test Mol Biomarkers</source><year>2012</year><volume>16</volume><issue>3</issue><fpage>174</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">22103580</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basar</surname><given-names>Y</given-names></name><name><surname>Salmayenli</surname><given-names>N</given-names></name><name><surname>Aksoy</surname><given-names>M</given-names></name><name><surname>Se&#x000e7;kin</surname><given-names>S</given-names></name><name><surname>Aydin</surname><given-names>M</given-names></name><name><surname>Ozk&#x000f6;k</surname><given-names>E</given-names></name></person-group><article-title>ACE gene polymorphism in peripheral vascular
disease</article-title><source>Horm Metab Res</source><year>2007</year><volume>39</volume><issue>7</issue><fpage>534</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">17611909</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name><name><surname>Ghaneialvar</surname><given-names>H</given-names></name><name><surname>Rahimi</surname><given-names>Z</given-names></name><name><surname>Nomani</surname><given-names>H</given-names></name><name><surname>Saidi</surname><given-names>M</given-names></name><name><surname>Bahrehmand</surname><given-names>F</given-names></name><etal/></person-group><article-title>The angiotensin converting enzyme D allele is an independent risk
factor for early onset coronary artery disease</article-title><source>Clin Biochem</source><year>2010</year><volume>43</volume><issue>15</issue><fpage>1189</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">20655894</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafiee</surname><given-names>SM</given-names></name><name><surname>Firoozrai</surname><given-names>M</given-names></name><name><surname>Salimi</surname><given-names>S</given-names></name><name><surname>Zand</surname><given-names>H</given-names></name><name><surname>Hesabi</surname><given-names>B</given-names></name><name><surname>Mohebbi</surname><given-names>A</given-names></name></person-group><article-title>Angiotensin converting enzyme DD genotype not associated with
increased risk of coronary artery disease in the Iranian
population</article-title><source>Pathophysiology</source><year>2010</year><volume>17</volume><issue>3</issue><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">20079615</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakhjavani</surname><given-names>M</given-names></name><name><surname>Esfahanian</surname><given-names>F</given-names></name><name><surname>Jahanshahi</surname><given-names>A</given-names></name><name><surname>Esteghamati</surname><given-names>A</given-names></name><name><surname>Nikzamir</surname><given-names>AR</given-names></name><name><surname>Rashidi</surname><given-names>A</given-names></name><etal/></person-group><article-title>The relationship between the insertion/deletion polymorphism of
the ACE gene and hypertension in Iranian patients with type 2
diabetes</article-title><source>Nephrol Dial Transplant</source><year>2007</year><volume>22</volume><issue>9</issue><fpage>2549</fpage><lpage>2553</lpage><pub-id pub-id-type="pmid">17478487</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikzamir</surname><given-names>A</given-names></name><name><surname>Nakhjavani</surname><given-names>M</given-names></name><name><surname>Golmohamadi</surname><given-names>T</given-names></name><name><surname>Dibai</surname><given-names>L</given-names></name></person-group><article-title>Association of angiotensin-converting enzyme gene
insertion/deletion polymorphism with metabolic syndrome in Iranians with
type 2 diabetes mellitus</article-title><source>Arch Iran Med</source><year>2008</year><volume>11</volume><issue>1</issue><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18154415</pub-id></element-citation></ref></ref-list></back></article>